Prognostic factors | CBCT-cTACE n = 196 | DSA-cTACE n = 141 | p value |
---|---|---|---|
Age, years, mean (range) | 62.3 (21‒91) | 63.3 (37‒90) | 0.407 |
Gender | |||
Male | 140 (71) | 94 (67) | 0.414 |
Female | 56 (29) | 47 (33) | |
Alcohol drinking | |||
No | 164 (84) | 119 (84) | 0.978 |
Yes | 32 (16) | 22 (16) | |
Hepatitis B virus carrier | |||
No | 99 (51) | 76 (54) | 0.614 |
Yes | 97 (49) | 65 (46) | |
Hepatitis C virus carrier | |||
No | 142 (72) | 105 (75) | 0.773 |
Yes | 54 (28) | 36 (25) | |
Child–Pugh Class | |||
A (5‒6) | 144 (73) | 96 (68) | 0.283 |
B (7) | 37 (19) | 27 (19) | |
B (8‒9) | 15 (8) | 18 (13) | |
ALBI score | |||
1 | 53 (27) | 35 (25) | 0.780 |
2 | 131 (67) | 95 (67) | |
3 | 12 (6) | 11 (8) | |
Total bilirubin, (mg/dl), median (range) | 0.87 (0.18‒2.87) | 0.98 (0.20‒2.95) | 0.154 |
Albumin, (ng/ml), median (range) | 3.6 (2.2‒4.7) | 3.4 (1.8‒4.8) | 0.064 |
INR, median (range) | 1.25 (1.0‒2.2) | 1.22 (0.9‒2.0) | 0.052 |
Platelet count, × 103/mm3, median (range) | 99 (30‒435) | 106 (35‒318) | 0.853 |
Serum AFP level (ng/ml) | |||
< 20 | 96 (49) | 56 (40) | 0.241 |
20‒200 | 57 (29) | 48 (34) | |
> 200 | 43 (22) | 37 (26) | |
Ascites | |||
No | 173 (88) | 117 (83) | 0.222 |
Yes | 23 (12) | 24 (17) | |
Size of largest tumor, mm, median (range) | 3.1 (1.1‒7.0) | 3.2 (1.1‒7.0) | 0.157 |
Tumor number | |||
1 | 108 (55) | 72 (51) | 0.179 |
2–3 | 64 (33) | 58 (41) | |
4–5 | 24 (12) | 11 (8) | |
Site of tumors | |||
Unilobar | 165 (84) | 118 (84) | 1.000 |
Bilobar | 31 (16) | 23 (16) | |
Up-to-7 criteria | |||
Within | 158 (81) | 109 (77) | 0.547 |
Beyond | 38 (19) | 32 (23) | |
BCLC-staging | |||
Stage A | 115 (59) | 71 (50) | 0.130 |
Stage B | 81 (41) | 70 (50) |